TG Therapeutics thrusts forward with Briumvi, eyeing a leading foothold in the multiple sclerosis therapy market—a high-risk, high-reward play.
Overview
TG Therapeutics, Inc. specializes in developing therapies for B-cell related diseases, notably Multiple Sclerosis (MS), with Briumvi as its flagship product. Since its 2023 launch, Briumvi has rapidly become the company's sole revenue driver, catalyzing profitability as it penetrates the large MS market and expands into Europe. The company's growth initiatives, further enriched by an innovative drug pipeline and a disciplined financial strategy, position it for continued commercial success.